Combination Phentermine-Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study.
Objective: The goal of this study was to obtain preliminary data on the usefulness of the combination of phentermine and topiramate extended release (phentermine-topiramate) in binge-eating disorder (BED) associated with obesity or overweight. Design: Ten participants with BED and obesity or overwei...
| Publicado en: | Innovations in Clinical Neuroscience Vol. 15; no. 5/6; pp. 17 - 22 |
|---|---|
| Autores principales: | , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Matrix Medical Communications, LLC
May/Jun2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=130481107&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 130481107 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 21588333 DAD5 jtl: Innovations in Clinical Neuroscience issn: 21588333 maglogo: N pubinfo: dt: May/Jun2018 vid: 15 iid: 5/6 pid: 33670 pub: Matrix Medical Communications, LLC place: West Chester, Pennsylvania artinfo: ui: 130481107 130481107 130481107 130481107 ppf: 17 ppct: 5 formats: fmt: @attributes: type: P tig: atl: Combination Phentermine-Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study. aug: au: GUERDJIKOVA, ANNA I. WILLIAMS, STEPHANIE BLOM, THOMAS J. MORI, NICOLE MCELROY, SUSAN L. affil: Lindner Center of HOPE in Mason, Ohio sug: subj: Amphetamines Therapeutic Use Topiramate Therapeutic Use Binge Eating Disorder Drug Therapy Drug Combinations Obesity Complications Binge Eating Disorder Etiology Prospective Studies Clinical Trials Human Body Weight Outcome Assessment Body Mass Index Severity of Illness Psychopathology Obsessive-Compulsive Disorder Amphetamines Administration and Dosage Topiramate Administration and Dosage Adverse Health Care Event Dysgeusia Medication Errors Weight Loss ab: Objective: The goal of this study was to obtain preliminary data on the usefulness of the combination of phentermine and topiramate extended release (phentermine-topiramate) in binge-eating disorder (BED) associated with obesity or overweight. Design: Ten participants with BED and obesity or overweightness with at least one weight-related complication received phentermine-topiramate in an open-label, prospective, 12-week trial. The primary outcome measure was change in weight. The study was registered under the identifier NCT02659475 at ClinicalTrials.gov. Results: Seven participants completed the study. Phentermine-topiramate treatment was associated with significant reductions in weight, body mass index, binge-eating episode frequency, and measures of global clinical severity, eating disorder psychopathology, and obsessive-compulsive symptoms. Mean daily dose of phentermine- topiramate at endpoint was 6.8 to 41.4mg per day. The most common adverse event (AE) was dysgeusia. There were no serious AEs, and no participants displayed symptoms of medication misuse or withdrawal. Conclusion: Phentermine- topiramate could be helpful for weight loss and reduction of binge-eating symptoms in patients with obesity or overweight in addition to BED. Controlled studies are warranted. pubtype: Academic Journal doctype: clinical trial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|